Cancer Diagnostics Partnering Terms and Agreements

  • May 2014
  • -
  • Currentpartnering
  • -
  • 1080 pages

The Cancer Diagnostics Partnering Agreements report provides an understanding and access to the cancer diagnostics partnering deals and agreements entered into by the worlds leading healthcare companies.

Trends in cancer diagnostics partnering deals
Disclosed headlines, upfronts, milestones and royalties by stage of development
Cancer diagnostics partnering contract documents
Top cancer diagnostics deals by value

The Cancer Diagnostics Partnering Agreements report provides an understanding and access to the cancer diagnostics partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides an understanding and analysis of how and why companies enter cancer diagnostics partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors diagnostics technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. The report also includes companion, imaging, CT, MRI, ultrasound, in vitro, molecular, prognostics and theranostics diagnostics deals and alliances.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This report contains over 900 links to online copies of actual cancer diagnostics deals and where available, contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The initial chapters of this report provide an orientation of cancer diagnostics dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in cancer diagnostics dealmaking since 2009, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading cancer diagnostics deals since 2009. Deals are listed by headline value and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 50 big pharma companies with a brief summary followed by a comprehensive listing of cancer diagnostics deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive and detailed review of cancer diagnostics partnering deals signed and announced since January 2009, where a contract document is available in the public domain. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc). Each deal title links via Weblink to an online version of the deal record providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of cancer diagnostics deals with a specific focus on oncology therapy area for deals since 2009. Each deal title links via Weblink to an online version of the deal record and where available links to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 7 provides a comprehensive and detailed review of cancer diagnostics deals with a specific focus on diagnostics technology area for deals since 2009. Each deal title links via Weblink to an online version of the deal record and where available links to an online version of the actual contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in cancer diagnostics partnering and dealmaking since 2009.

In addition, a comprehensive appendix is provided organized by cancer diagnostics partnering company A-Z , deal type definitions and cancer diagnostics partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of cancer diagnostics technologies and products.

Report scope

Cancer Diagnostics Partnering Agreements is intended to provide the reader with an in-depth understanding and access to cancer monoclonal antibody trends and structure of deals entered into by leading companies worldwide.

Cancer Diagnostics Partnering Agreements includes:

Trends in cancer diagnostics dealmaking in the biopharma industry since 2009
Analysis of cancer diagnostics deal structure
Access to headline, upfront, milestone and royalty data
Access to over 900 cancer diagnostics deal records
The leading cancer diagnostics deals by value since 2009
Includes companion, imaging, CT, MRI, ultrasound, in vitro, molecular, prognostics and theranostics diagnostics deals and alliances since 2007

In Cancer Diagnostics Partnering Agreements, the available deals are listed by:

Company A-Z
Headline value
Stage of development at signing
Deal component type
Specific oncology therapy target
DIagnostics type

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Cancer Diagnostics Agreements report provides comprehensive access to available deals and contract documents for over 900 cancer diagnostics deals. Analyzing actual contract agreements allows assessment of the following:

What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How aresales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?

Cancer Diagnostics Partnering Agreements provides the reader with the following key benefits:

In-depth understanding of cancer diagnostics deal trends since 2009
Access to headline, upfront, milestone and royalty data
Acces to the structure of cancer diagnostics agreements with numerous real life case studies
Comprehensive access to over 900 actual cancer diagnostics deals entered into by the world’s biopharma companies
Insight into the terms included in a cancer diagnostics agreement, together with real world clause examples
Understand the key deal terms companies have agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Table Of Contents

Executive Summary
Chapter 1 - Introduction
Chapter 2 - Trends in cancer diagnostics dealmaking
2.1. Introduction
2.2. Cancer diagnostics partnering over the years
2.3. Big pharma cancer diagnostics dealmaking activity
2.4 Most active cancer diagnostics dealmakers
2.5. Cancer diagnostics partnering by deal type
2.6. Cancer diagnostics partnering by stage of development
2.7. Cancer diagnostics partnering by cancer indication
2.8. Cancer diagostics partnering by specific technology type
2.9. Disclosed deal terms for cancer diagnostics partnering
2.9.1 Cancer diagnostics partnering headline values
2.9.2 Cancer diagnostics deal upfront payments
2.9.3 Cancer diagnostics deal milestone payments
2.9.4 Cancer diagnostics royalty rates

Chapter 3 - Leading cancer diagnostics deals
3.1. Introduction
3.2. Top cancer diagnostics deals by value

Chapter 4 - Big pharma cancer diagnostics deals
4.1. Introduction
4.2. How to use big pharma partnering deals
4.3. Big pharma cancer diagnostics partnering company profiles
Abbott
Amgen
Astellas
AstraZeneca
Bayer
Biogen Idec
Boehringer Ingelheim
Bristol-Myers Squibb
Celgene
Eisai
Eli Lilly
Gilead Sciences
GlaxoSmithKline
Grifols
Johnson and Johnson
Merck and Co
Merck KGaA
Novartis
Pfizer
Roche
Sanofi
Servier
Teva
Chapter 5 - Cancer diagnostics dealmaking contracts directory
5.1. Introduction
5.2. Company A-Z
5.3. By stage of development
Discovery
Marketed
Phase III
Preclinical
5.4. By deal type
Asset purchase
Co-development
Collaborative RandD
Co-market
Contract service
Co-promotion
Development
Distribution
Equity purchase
Evaluation
Licensing
Manufacturing
Marketing
Option
Research
Sub-license
Supply
Termination

Chapter 6 - Cancer diagnostics dealmaking by specific therapy type
6.1. Introduction
6.2. Deals by oncology type
Oncology

Chapter 7 - Cancer diagnostics dealmaking by specific technology type
7.1. Introduction
7.2. Deals by diagnostics type
Diagnostics

Chapter 8 -Partnering resource center
8.1. Online partnering
8.2. Partnering events
8.3. Further reading on dealmaking
About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from CurrentPartnering
Order Form - Therapy Reports
Appendix
Appendix 1 - Deal type definitions
Appendix 2 - Example cancer diagnostics partnering agreement
Appendix 3 - Cancer Diagnostics deals directory 2009-2014: Company A-Z.
Appendix 4 - Cancer diagnostics deals directory 2009-2014: By deal type
Appendix 5 - Cancer diagnostics deals directory 2009-2014: By stage of development

Table of figures

Figure 1: Cancer diagnostics partnering since 2009
Figure 2: Big pharma - top 50 - cancer diagnostics deals 2009 to 2014
Figure 3: Big pharma cancer diagnostics deal frequency - 2009 to 2014
Figure 4: Active cancer diagnostics dealmaking activity- 2009 to 2014
Figure 5: Cancer diagnostics partnering by deal type since 2009
Figure 6: Cancer diagnostics partnering by stage of development since 2009
Figure 7: Cancer diagnostics partnering by oncology target since 2009
Figure 8: Cancer diagnostics partnering by diagnostics technology type since 2009
Figure 9: Cancer diagnostics deals with a headline value - by stage of development
Figure 10: Cancer diagnostics deal headline value distribution, US$million - discovery stage
Figure 11: Cancer diagnostics deal headline value distribution, US$million - preclinical stage
Figure 12: Cancer diagnostics deal headline value distribution, US$million - phase I stage
Figure 13: Cancer diagnostics deal headline value distribution, US$million - phase II stage
Figure 14: Cancer diagnostics deal headline value distribution, US$million - phase III stage
Figure 15: Cancer diagnostics deal headline value distribution, US$million - regulatory stage
Figure 16: Cancer diagnostics deal headline value distribution, US$million - marketed stage
Figure 17: Cancer diagnostics deal headline value - median value by stage of development
Figure 18: Cancer diagnostics deals with upfront payment values - by stage of development
Figure 19: Cancer diagnostics deal upfront distribution, US$million - discovery stage
Figure 20: Cancer diagnostics deal upfront value distribution, US$million - preclinical stage
Figure 21: Cancer diagnostics deal upfront value distribution, US$million - phase I stage
Figure 22: Cancer diagnostics deal upfront value distribution, US$million - phase II stage
Figure 23: Cancer diagnostics deal upfront value distribution, US$million - phase III stage
Figure 24: Cancer diagnostics deal upfront value distribution, US$million - regulatory stage
Figure 25: Cancer diagnostics deal upfront value distribution, US$million - marketed stage
Figure 26: Cancer diagnostics deal upfront value - median value by stage of development
Figure 27: Cancer diagnostics deals with milestone payment - by stage of development
Figure 28: Cancer diagnostics deal milestone distribution, US$million - discovery stage
Figure 29: Cancer diagnostics deal milestone value distribution, US$million - preclinical stage
Figure 30: Cancer diagnostics deal milestone value distribution, US$million - phase I stage
Figure 31: Cancer diagnostics deal milestone value distribution, US$million - phase II stage
Figure 32: Cancer diagnostics deal milestone value distribution, US$million - phase III stage
Figure 33: Cancer diagnostics deal milestone value distribution, US$million - regulatory stage
Figure 34: Cancer diagnostics deal milestone value distribution, US$million - marketed stage
Figure 35: Cancer diagnostics deals with royalty rates
Figure 36: Cancer diagnostics deal royalty rate distribution, US$million - discovery stage
Figure 37: Cancer diagnostics deal royalty rate value distribution, US$million - preclinical stage
Figure 38: Cancer diagnostics deal royalty rate value distribution, US$million - phase I stage
Figure 39: Cancer diagnostics deal royalty rate value distribution, US$million - phase II stage
Figure 40: Cancer diagnostics deal royalty rate value distribution, US$million - phase III stage
Figure 41: Cancer diagnostics deal royalty rate value distribution, US$million - regulatory stage
Figure 42: Cancer diagnostics deal royalty rate value distribution, US$million - marketed stage
Figure 43: Cancer diagnostics deal royalty value - median value by stage of development
Figure 44: Top cancer diagnostics deals by value since 2009
Figure 45: Online partnering resources
Figure 46: Forthcoming partnering events

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

2014 Market Segmentation Analysis of the Global Cancer Diagnostics Industry: Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Hospitals, Commercial Labs, POC Locations

2014 Market Segmentation Analysis of the Global Cancer Diagnostics Industry: Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Hospitals, Commercial Labs, POC Locations

  • $ 34 500
  • Industry report
  • July 2014
  • by Venture Planning Group

Complete report $34,500.  DataPack (test volumes, sales forecasts, supplier shares) $21,100.  The report is available by country, section, market segment, and can be custom-tailored to your specific ...

Emerging Opportunities in the Global Virology and Bacteriology Testing Market

Emerging Opportunities in the Global Virology and Bacteriology Testing Market

  • $ 21 100
  • Industry report
  • June 2014
  • by Venture Planning Group

“Emerging Opportunities in the Global Virology and Bacteriology Testing Market” is a new seven-country strategic analysis of major business opportunities emerging in the infectious disease testing ...

Future Horizons and Growth Strategies in the Global Microbiology Testing Market 2014: Supplier Shares and Country Forecasts

Future Horizons and Growth Strategies in the Global Microbiology Testing Market 2014: Supplier Shares and Country Forecasts

  • $ 21 100
  • Industry report
  • August 2014
  • by Venture Planning Group

Complete report $32,500.  DataPack (test volumes, sales forecasts, supplier shares) $21,100. “2014 Strategies for the Global Microbiology Testing Market” is a new seven-country strategic analysis ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.